Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Ilava – page 10

209 clinical trials in Ilava, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Ilava at a glance
209
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

209 trials in Ilava

Open in trial search

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Arteriosclerosis

Not recruiting

Study on the Effect of Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease Not Adequately Managed by Current Lipid-Lowering Treatments

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Obicetrapib
  • Sponsor:NewAmsterdam Pharma B.V.

Study on Tofacitinib for Patients with Early Active Axial Spondyloarthritis Who Did Not Respond to NSAIDs

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Naproxen
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Asthma

Not recruiting

Study on the Safety of CHF5993 Inhaler with HFA-152a vs. HFA-134a in Patients with Moderate to Severe Asthma

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:Chiesi Farmaceutici S.p.A.

Gout

Not recruiting

Study on the Effects of Tigulixostat and Allopurinol in Patients with Gout and High Uric Acid Levels

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol
  • Sponsor:LG Chem Ltd.

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Sun Pharmaceutical Industries Limited

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Izokibep
  • Sponsor:Acelyrin Inc.

Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Atrial fibrillation

Not recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:SlovakiaSlovakia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Ilava

What the registry says about research in the country

01 Cardiovascular Diseases

The clinical trial activity in Ilava includes research in cardiovascular diseases, with a focus on improving protection against major heart-related events and related complications. These studies are exploring new ways to reduce risk in people living with established or high-risk heart conditions.

  • Atherosclerotic cardiovascular disease
  • Established cardiovascular disease
  • High cardiovascular risk
  • Hypertension

The goal is to evaluate whether new treatments can better prevent serious outcomes such as heart attack, stroke, heart failure, and cardiovascular death.

02 Nutritional and Metabolic Diseases

Another key area in this research landscape is nutritional and metabolic diseases, especially conditions linked to excess weight and metabolic risk. The trials are looking at therapies that may support weight reduction while also improving broader health outcomes.

  • Obesity
  • Overweight
  • Chronic kidney disease

In Ilava, this work is aimed at understanding whether newer treatments can help lower the burden of obesity-related complications and support kidney health at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.